» Articles » PMID: 21841316

Human Breast Cancer Cells Enhance Self Tolerance by Promoting Evasion from NK Cell Antitumor Immunity

Abstract

NK cells are a major component of the antitumor immune response and are involved in controlling tumor progression and metastases in animal models. Here, we show that dysfunction of these cells accompanies human breast tumor progression. We characterized human peripheral blood NK (p-NK) cells and malignant mammary tumor-infiltrating NK (Ti-NK) cells from patients with noninvasive and invasive breast cancers. NK cells isolated from the peripheral blood of healthy donors and normal breast tissue were used as controls. With disease progression, we found that expression of activating NK cell receptors (such as NKp30, NKG2D, DNAM-1, and CD16) decreased while expression of inhibitory receptors (such as NKG2A) increased and that this correlated with decreased NK cell function, most notably cytotoxicity. Importantly, Ti-NK cells had more pronounced impairment of their cytotoxic potential than p-NK cells. We also identified several stroma-derived factors, including TGF-β1, involved in tumor-induced reduction of normal NK cell function. Our data therefore show that breast tumor progression involves NK cell dysfunction and that breast tumors model their environment to evade NK cell antitumor immunity. This highlights the importance of developing future therapies able to restore NK cell cytotoxicity to limit/prevent tumor escape from antitumor immunity.

Citing Articles

Efficacy Evaluation of "Enhanced" Natural Killers with and Knockouts on Viability and Metabolic Status of 3D Glioblastoma Spheroid Cells in Patients.

Yuzhakova D, Sachkova D, Shirmanova M, Shcheslavskiy V, Mozherov A, Dashinimaev E Sovrem Tekhnologii Med. 2025; 17(1):109-118.

PMID: 40071076 PMC: 11892565. DOI: 10.17691/stm2025.17.1.10.


Early-Stage Luminal B-like Breast Cancer Exhibits a More Immunosuppressive Tumor Microenvironment than Luminal A-like Breast Cancer.

Moura T, Caramelo O, Silva I, Silva S, Goncalo M, Portilha M Biomolecules. 2025; 15(1).

PMID: 39858472 PMC: 11763923. DOI: 10.3390/biom15010078.


Natural killer cells occupy unique spatial neighborhoods in HER2 and HER2 human breast cancers.

Ehlers F, Blise K, Betts C, Sivagnanam S, Kooreman L, Hwang E Breast Cancer Res. 2025; 27(1):14.

PMID: 39856748 PMC: 11762118. DOI: 10.1186/s13058-025-01964-4.


The diversity of natural killer cell functional and phenotypic states in cancer.

Rishabh K, Matosevic S Cancer Metastasis Rev. 2025; 44(1):26.

PMID: 39853430 DOI: 10.1007/s10555-025-10242-w.


AXL: shapers of tumor progression and immunosuppressive microenvironments.

Liu Y, Xu L, Dou Y, He Y Mol Cancer. 2025; 24(1):11.

PMID: 39799359 PMC: 11724481. DOI: 10.1186/s12943-024-02210-9.


References
1.
Luci C, Reynders A, Ivanov I, Cognet C, Chiche L, Chasson L . Influence of the transcription factor RORgammat on the development of NKp46+ cell populations in gut and skin. Nat Immunol. 2008; 10(1):75-82. DOI: 10.1038/ni.1681. View

2.
McGilvray R, Eagle R, Watson N, Al-Attar A, Ball G, Jafferji I . NKG2D ligand expression in human colorectal cancer reveals associations with prognosis and evidence for immunoediting. Clin Cancer Res. 2009; 15(22):6993-7002. PMC: 2778653. DOI: 10.1158/1078-0432.CCR-09-0991. View

3.
Moretta L, Bottino C, Pende D, Castriconi R, Mingari M, Moretta A . Surface NK receptors and their ligands on tumor cells. Semin Immunol. 2006; 18(3):151-8. DOI: 10.1016/j.smim.2006.03.002. View

4.
Swann J, Smyth M . Immune surveillance of tumors. J Clin Invest. 2007; 117(5):1137-46. PMC: 1857231. DOI: 10.1172/JCI31405. View

5.
Moretta A, Bottino C, Vitale M, Pende D, Cantoni C, Mingari M . Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol. 2001; 19:197-223. DOI: 10.1146/annurev.immunol.19.1.197. View